In last trading session, Atossa Therapeutics Inc (NASDAQ:ATOS) saw 0.68 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.84 trading at -$0.03 or -3.17% at ring of the bell on the day assigns it a market valuation of $108.75M. That closing price of ATOS’s stock is at a discount of -97.62% from its 52-week high price of $1.66 and is indicating a premium of 34.52% from its 52-week low price of $0.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.7 million shares which gives us an average trading volume of 977.09K if we extend that period to 3-months.
For Atossa Therapeutics Inc (ATOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Atossa Therapeutics Inc (NASDAQ:ATOS) trade information
Atossa Therapeutics Inc’s shares saw a change of -39.86% in year-to-date performance and have moved -10.29% in past 5-day. Atossa Therapeutics Inc (NASDAQ:ATOS) showed a performance of 3.87% in past 30-days. Number of shares sold short was 7.42 million shares which calculate 9.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 83.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -495.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -495.24% for stock’s current value.
Atossa Therapeutics Inc (ATOS) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.92% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -16.25% while estimates for its earnings growth in next 5 years are of -14.47%.
Atossa Therapeutics Inc (NASDAQ:ATOS)’s Major holders
Insiders are in possession of 0.07% of company’s total shares while institution are holding 26.58 percent of that, with stock having share float percentage of 26.60%. Investors also watch the number of corporate investors in a company very closely, which is 26.58% institutions for Atossa Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ATOS for having 9.2 million shares of worth $10.94 million. And as of 2024-06-30, it was holding 7.3148 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 6.49 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.1585 of outstanding shares, having a total worth of $7.72 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.94 shares of worth $3.32 million or 3.05% of the total outstanding shares. The later fund manager was in possession of 3.15 shares on May 31, 2025 , making its stake of worth around $2.65 million in the company or a holder of 2.44% of company’s stock.
